There is increasing randomized control trial data that CGMs are of benefit for people with T2DM not on insulin [14, 44], and further studies on long-term clinical outcomes (hospitalizations, emergency visits, diabetes-related complications, etc.)and cost-benefit analysis in socially minoritized and marginalized patient populations are needed to guide additional access expansion to those not on insulin to address disparities in diabetes outcomes. Here, INS is linked to type 2 diabetes mellitus.